Starpharma SPL7013 Nasal Spray for COVID-19 – Development Update

Author's Avatar
Aug 25, 2020
Article's Main Image

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced progress with development, regulatory and manufacturing activities associated with a nasal spray for protection against COVID-19 based on the company’s proprietary antiviral dendrimer, SPL7013.